Marking expansion of Avantor’s global pharmaceutical manufacturing base, the Indian Food and Drug Administration approved and certified plant will produce and package the company’s Macron Fine Chemicals brand of salts and solvents.
Avantor global pharmaceuticals executive vice president Paul Smaltz said, "The availability of cGMP chemicals from our Panoli facility demonstrates Avantor’s continued growth as a leading global manufacturer and supplier of high-quality performance materials."
The chemicals will be used for the production of pharmaceuticals and in chromatography separations for laboratory research, drug development and discovery.
The Macron Fine Chemicals products from the facility will meet Indian Pharmacopeia (IP), United States Pharmacopeia (USP), National Formulary (NF), European Pharmacopeia (EP), Japanese Pharmacopeia (JP) and British Pharmacopeia (BP) standards.
Construction of the plant began in 2011 after receiving the facility as part of its acquisition of RFCL Limited, and the cGMP production commenced in January 2013.